GlassScriptPhysician profile
Aaron J Reiprich
NPI 1306287560
$6,376.55
in general payments reported to CMS, 2019-2025
36 companies · $1,444 in 2025
The $1,444 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $645 · 2020: $457 · 2021: $716 · 2022: $743 · 2023: $1,309 · 2024: $1,062 · 2025: $1,444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,796 · Education: $19.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,796.10 |
| Education | $19.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,366.06 | 2019-2025 | |
| Janssen Biotech, INC. | $1,029.75 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $573.03 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $424.98 | 2019-2025 | Eohilia, Entyvio, Gattex |
| Boston Scientific Corporation | $181.08 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $172.49 | 2023-2025 | Dupixent |
| Allergan, INC. | $141.22 | 2020 | |
| Daiichi Sankyo INC. | $130.72 | 2019-2023 | Injectafer |
| Ardelyx, INC. | $120.78 | 2023-2024 | Ibsrela |
| Pfizer INC. | $120.00 | 2019-2024 | |
| Genzyme Corporation | $110.60 | 2022-2025 | |
| Celgene Corporation | $106.38 | 2022-2023 | Zeposia |
| Merck Sharp & Dohme LLC | $104.96 | 2021-2024 | Dificid |
| Ferring Pharmaceuticals INC. | $90.33 | 2019-2021 | |
| Qol Medical, LLC | $73.05 | 2022-2023 | Sucraid |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $69.95 | 2025 | Wegovy |
| Celltrion USA INC. | $60.85 | 2024-2025 | Vegzelma, Zymfentra |
| Phathom Pharmaceuticals, INC. | $49.89 | 2023-2025 | Voquezna |
| Madrigal Pharmaceuticals | $48.65 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $40.46 | 2022 | |
| Lilly USA, LLC | $39.54 | 2024 | Omvoh |
| Cook Medical LLC | $38.95 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.48 | 2023 | Cyltezo |
| Ucb, INC. | $35.29 | 2019 | |
| Romark Laboratories, Lc | $32.58 | 2019 | |
| Nestle Healthcare Nutrition INC. | $26.16 | 2021 | |
| Amgen INC. | $25.25 | 2023 | Amjevita |
| Ipsen Biopharmaceuticals, INC | $16.35 | 2025 | Iqirvo |
| Micro-Tech Endoscopy USA, INC. | $15.54 | 2023 | Lesionhunter |
| Braintree Laboratories, INC. | $14.96 | 2021 | |
| Alexion Pharmaceuticals, INC. | $14.88 | 2019 | |
| Alnylam Pharmaceuticals INC. | $14.48 | 2022 | |
| Olympus America INC. | $14.44 | 2019 | |
| Aimmune Therapeutics, INC. | $13.37 | 2024 | |
| Redhill Biopharma INC. | $11.82 | 2020 | |
| Gilead Sciences, INC. | $11.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Reiprich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.